Science Explorer Back to mapMap

Most cited papers from Ocuphire Pharma (United States)

What are the most cited papers from Ocuphire Pharma (United States)?

The most cited paper from Ocuphire Pharma (United States) is "APE1/Ref-1 as a Novel Target for Retinal Diseases" (Curtis J. Heisel, Jonah E. Yousif, Mahmut Mijiti et al., 2021), with 20 citations. Next come "Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial" (12) and "Prevalence Estimates and Genetic Diversity for Autosomal Dominant Retinitis Pigmentosa Due to RHO, c.68C>A (p.P23H) Variant" (8).

Showing 11 of 11 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 APE1/Ref-1 as a Novel Target for Retinal Diseases Curtis J. Heisel, Jonah E. Yousif, Mahmut Mijiti et al. · Journal of Cellular Signaling Open access 30 Jun 2021 20
2 Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial Jay S. Pepose, Paul J. Hartman, Harvey B. Dubiner et al. · Clinical ophthalmology Open access 2021 12
3 Prevalence Estimates and Genetic Diversity for Autosomal Dominant Retinitis Pigmentosa Due to RHO, c.68C>A (p.P23H) Variant Matthijs Leenders, Mathijs Gaastra, Ash Jayagopal et al. · American Journal of Ophthalmology 14 Sep 2024 8
4 A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances Jay S. Pepose, Mitchell Brigell, Eliot S. Lazar et al. · BMC Ophthalmology Open access 8 Oct 2022 5
5 Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial Paul M Karpecki, Shane A. Foster, Stephen M. Montaquila et al. · Optometry and Vision Science 27 Feb 2021 5
6 Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution Jay S. Pepose, David Wirta, David Evans et al. · Ophthalmology Open access 16 Sep 2024 3
7 Phentolamine mesylate ophthalmic solution provides long lasting pupil modulation and improves visual acuity Jay S. Pepose, Bill Pitlick, Alan R. Meyer et al. · Investigative Ophthalmology & Visual Science Open access 10 Jun 2020 1
8 Vega-1: A Phase 3, Double-Masked, Randomized, Placebo-Controlled Study Of Pos And Ldp In Presbyopic Patients Mina Sooch, LOUIS HADDAD, Kavon Rahmani et al. · ESCRS Abstracts Open access 31 Mar 2026 0
9 Treatment With 0.75% Phentolamine Ophthalmic Solution Reverses Mydriasis In Healthy Subjects: Results From Mira-2 And Mira-3, Pivotal Phase 3 Clinical Trials Mitchell A. Jackson, Mina Sooch, Drey Coleman et al. · ESCRS Abstracts Open access 31 Mar 2026 0
10 Oral Apx3330 Reduces The Drss Worsening After 24-Weeks Of Daily Treatment: Efficacy And Safety Results Of The Zeta-1 Phase 2 Trial In Diabetic Retinopathy Mina Sooch, LOUIS HADDAD, Mitchell Brigell et al. · ESCRS Abstracts Open access 31 Mar 2026 0
11 Lynx-1: Phentolamine Ophthalmic Solution For Dim Light Vision Disturbance Mina Sooch, Obaidah Bitar, LOUIS HADDAD et al. · ESCRS Abstracts Open access 31 Mar 2026 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.